Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients
Diabetes, Obesity and Metabolism · 2026
DOI: 10.1111/dom.70938 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes, Obesity and Metabolism, 2026. Verfasst von Hyung Seok John Kim und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Practice, Sciences, and Health Outcomes Research, University of Maryland Baltimore, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Sleep Apnea, Obstructive, Health Care Costs, Cost of Illness, Overweight. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Aims
To quantify the incremental economic and utilization burden of comorbid obstructive sleep apnea (OSA) within an overweight to severely obese adult population. Material and Methods This retrospective cohort study utilized 2016–2025 IQVIA PharMetrics Plus Closed Health Plan commercial claims data to identify overweight to severely obese adults aged 18–64 years. Patients with diagnosed OSA were propensity‐score matched 1:1 to non‐OSA controls. Generalized linear models were constructed to quantify the incremental burden of OSA through adjusted cost/rate ratios and average marginal effects (AMEs) over a 365‐day follow up period. Outcomes were also stratified by obesity severity, cardiovascular disease (CVD), diabetes, sex, and baseline glucagon‐like peptide‐1 receptor agonist (GLP‐1 RA) use.
Results
Among OSA patients, 13 971 (99.9%) were successfully matched (total n = 27 942). Patients with OSA incurred significantly higher total healthcare costs compared to controls (adjusted cost ratio = 1.24; 95% CI = [1.20, 1.28]), corresponding to an AME of $6942 per patient. Costs were driven by routine disease management such as outpatient visits (AME = $2955) and prescription costs (AME = $3198). Subgroup analyses revealed that incremental costs were high among patients with CVD (AME = $9257) and notably, the incremental cost of OSA remained substantial even among chronic users of GLP‐1 RAs (AME = $12359).
Conclusion
Comorbid OSA is associated with a significant increase in total healthcare costs driven largely by outpatient and prescription costs. This burden was concentrated among patients with cardiovascular comorbidity and persisted among chronic GLP‐1 RA users.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Practice, Sciences, and Health Outcomes Research, University of Maryland Baltimore, Baltimore, Maryland, USA.
- University of California San Diego, San Diego, California, USA.
ORCID-Profile: Hyung Seok John Kim, Tien Hoang Tran
Förderung
- NHLBI NIH HHS
Zitieren
APA
Kim, H. S. J., Tran, T. H., Schmickl, C. N., & Slejko, J. F. (2026). Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.70938
Vancouver
Kim HSJ, Tran TH, Schmickl CN, Slejko JF. Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients. Diabetes, Obesity and Metabolism. 2026. doi:10.1111/dom.70938
BibTeX
@article{Kim2026,
author = {Kim, Hyung Seok John and Tran, Tien Hoang and Schmickl, Christopher N and Slejko, Julia F},
title = {Investigating the Incremental Cost and Utilization Burden of Obstructive Sleep Apnea in Overweight to Severely Obese Patients},
journal = {Diabetes, Obesity and Metabolism},
year = {2026},
doi = {10.1111/dom.70938}
}
EUVIMED